Background/Aims: Recent studies have reported the importance of tubulin alpha 4b (TUBA4B), a long non-coding RNA, in the development of several cancers; however, studies on its clinical significance are rare. In the present meta-analysis, we investigated whether TUBA4B can be used as a prognostic biomarker in human cancers. Methods: A comprehensive search was performed in PubMed, Embase, Web of Science, and the Gene Expression Omnibus databases. Hazard ratios from individual studies were calculated and pooled using a random-effects or fix-effects model. The pooled hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the value of TUBA4B. The expression of TUBA4B was evaluated in lung cancer tissue arrays by fluorescence in situ hybridization assay. Additionally, a sensitivity analysis and Begg's test were conducted. Results: We found that TUBA4B was significantly correlated with overall survival (OS) (HR = 1.33, 95% CI: 1.16-1.52, P=0.000), disease-free survival (DFS; HR = 1.25, 95% CI: 1.06-1.48, P=0.007), and recurrence-free survival (RFS; HR = 1.42, 95% CI: 1.26-1.60, P=0.000). In addition, TUBA4B was a risk factor for lung cancer (HR = 1.24, 95% CI: 1.03-1.49, P=0.021), colon cancer (HR = 1.67, 95% CI: 1.02-2.74, P=0.042), breast cancer (HR = 1.52, 95% CI: 1.10-2.12, P=0.012), and ovarian cancer (HR = 1.67, 95% CI: 1.18-2.36, P=0.004). Moreover, LncRNA-TUBA4B was significantly lower expression in tumor tissues than normal lung tissues (P<0.001). The expression of lncRNA-TUBA4B was decreased with the progression of lung cancer stage. A subgroup meta-analysis based on data resource, sample size, region, patient numbers, and tumor type was further performed. Our studies revealed that tumor tissues with low levels of TUBA4B was significantly associated with short OS, DFS, and RFS in cancer patients. Conclusion: The present findings suggest that TUBA4B can be a novel biomarker for the prognosis of various cancers.
Introduction
According to the GLOBOCAN estimates, approximately 14.1 million new cancer cases and 8.2 million deaths occurred worldwide in 2012 [1] . Cancer has become an increasingly serious problem worldwide. Early diagnosis and treatment are critical to improve the prognosis and survival of cancer patients. Furthermore, tumor molecular markers are of a great practical value in tumor screening, diagnosis, and prognosis; in evaluation of treatment efficacy; and for the follow-up of high-risk populations [2] . The molecular mechanisms underlying cancer development remain unclear; as such, the overall rate of cancer-related deaths are expected to increase. Therefore, identifying novel biomarker for diagnosis or prognosis is necessary to develop better therapeutic strategies to control cancer.
Recently, long non-coding RNAs (lncRNAs) have been identified to play important role as critical regulators of prognosis, pathogenesis, and biological processes in various cancers [3] [4] [5] . Furthermore, lncRNAs have important potential applications in the diagnosis and treatment of malignant tumors [6] [7] [8] . Recent studies have shown that various lncRNAs can act as tumor markers [9] [10] [11] .
Tubulin alpha 4b (TUBA4B) is a human protein significantly related with tumor progression. The low expression of TUBA4B can promote cell proliferation, advanced TNM stage, and lymph node metastasis in non-small-cell lung cancer [12] . Furthermore, TUBA4B is closely related with cell proliferation, migration, pathological grade, International Federation of Gynecology and Obstetrics stage, and lymph node metastases in ovarian cancer, and an increased expression of lncRNA-TUBA4B can attenuate the activation of ERK and AKT signaling pathways [13] . Thus, low levels of TUBA4B expression may be related to tumor prognosis.
However, most studies on TUBA4B are limited by their small sample size and discrete outcomes, and only few studies have investigated its prognostic significance in clinical tumor specimens. The Gene Expression Omnibus (GEO) database stores a massive amount of information on gene expression profiles in many tumor types. TUBA4B gene expression has been measured in this data set. Therefore, we systematically analyzed all previously published literature and the GEO database and performed a quantitative meta-analysis to evaluate the value of TUBA4B as a prognostic marker in human cancers.
Materials and Methods

Study strategy
Systematic literature searches were conducted in PubMed, Embase, and Web of Science. The literature search was conducted up to October 2017 and was limited to the English language. To increase the sensitivity of the search, both MeSH terms and free words were used. The search terms included "TUBA4B," "Tubulin, Alpha 4b," "long non-coding RNA" or "lncRNA," "cancer" or "carcinoma," "tumor" or "neoplasm," and "prognosis" or "survival." We also obtained microarray data, including overall survival (OS), disease-free survival (DFS), or recurrence-free survival (RFS), from the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array, HG-U133_Plus_2) from the GEO database. GEO database come from a variety of sources. To reduce data source variability, we selected only one platform (GPL570 platform) to minimize the impact on the heterogeneity in latter analysis.
Study selection
We manually searched and retrieved references for potentially missing literatures. First, the cited articles were excluded from duplicates, and then titles and abstracts were carefully scanned to eliminate irrelevant studies. The inclusion criteria are as follows: (a) TUBA4B expression in human tissues was measured and analyzed; (b) the relationship between TUBA4B expression and OS, DFS, or RFS was identified; (c) the survival curve or sufficient relevant data were provided to obtain hazard ratios (HR) for survival rates and their 95% confidence intervals (95% CI).
The exclusion criteria are as follows: (a) studies were excluded if they were letters, case reports, reviews, or conference reports; (b) the required data could not be extracted or calculated from the original article; (c) the article could not be found in full or had been published repeatedly. When the same data subsets were published in more than one article, only the latest publication was included.
Data extraction
Eligible data were independently evaluated and double checked from available studies based on the inclusion and exclusion criteria by each of the six investigators. The following items were extracted: first author, publication year, country, tumor type, sample size, clinical stage of tumor, test methods for TUBA4B expression, outcome measures, HR value, 95% CI of HR, survival analysis, HR extraction method, and quality score. HR, as a dominant indicator of interest, was extracted from multivariable and univariate analyses. If the articles only provided survival curves without directly detailing the HR and standard error (SE), appropriate data were extracted from the survival curves using Engauge Digitizer 4.1 as described previously [14] .
For the GEO database that included TUBA4B expression and related survival data, patient data, such as OS, DFS, RFS, survival outcome, follow-up, cutoff value, HR value, and 95% CI of HR, were extracted.
Quality assessment of the primary studies
The 2 eligible studies in our meta-analysis were each assessed for quality according to the NewcastleOttawa Scale [15, 16] . The score of all included studies was 7 and 8, with a mean of 7.5. A study with a higher score denoted a better methodological quality. The final scores are shown in Table 1 .
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) kit was purchased from Shanghai Gefan Biotech Co., Ltd. (Shanghai, China) and lung cancer tissue arrays (HLugA180Su05, containing 94 patients-86 normal tissues and 94 cancer tissues) were purchased from Shanghai Outdo Biotech Co., Ltd. (Shanghai, China). Tissue sections were deparaffinized and rehydrated. FISH assay was performed according to manufacturer instructions. The probe used for lncRNA-TUBA4B was Homo 5'-FAM-ugcacuggucagccagcuuccgaauccggu-3'.
Statistical analysis
We calculated the HR values and their corresponding 95% CI, OS, DFS, RFS, and Kaplan-Meier curves using GraphPad Prism 5.0. The cut-off value of differently expressed lncRNA-TUBA4B was set to be a ≥1.5-fold difference, and the false discovery ratio was <0.05. We then analyzed the obtained data for OS, DFS, RFS, and other factors using STATA version 12.0 software (Stata Corporation, Collage Station, Texas, USA). For OS, DFS, and RFS, we merged the HR values and performed heterogeneity tests. I 2 > 50% was defined as significant heterogeneity [17] . If significant heterogeneity existed between studies, we used a random effects model and performed subgroup analyses or used the fixed effects model to analyze combined HR values and 95% CI. All graphical representations were generated as forest plots. HR is the ratio of the prognosis in the case of high TUBA4B expression to the prognosis in the case of low TUBA4B expression. HR>1 indicates that the patients with high TUBA4B expression have a good prognosis, and HR<1 indicates that the patients with low TUBA4B expression have a poor prognosis. For the studies from which we could obtain OS and DFS data, we constructed a funnel plot to describe publication bias using SelnHR as the abscissa and lnHR as the ordinate. We subsequently tested the funnel plot and evaluated publication bias via a linear regression model using STATA 12.0 (Begg's test and Egger's test). Sensitivity analyses were conducted for the HR and OS values of TUBA4B extracted from the individual studies using STATA version 12.0. The results of FISH assay were performed with the statistical program GraphPad Prism 7.0 (GraphPad, San Diego, CA, USA). Statistical analyses were performed using two-tailed Student's t-test to derive the significance of the differences between two groups. P<0.05 was considered statistically significant.
Results
Study eligibility
A total of 8 articles were identified from a search of the databases. After excluding 5 duplicate publications, 3 were included for further screening. After carefully reviewing the title and abstract, as well as the full text, 2 studies were finally selected based on the inclusion and exclusion criteria described in the methodology section. In addition, as shown in Fig. 1 , 33 studies based on Affymetrix Human Genome U133 Plus 2.0 Array were downloaded from the GEO database.
Study characteristics
As shown in Table 1 , the publication year of the articles ranged from 2016 to 2017. A total of 230 cases from 2 included eligible studies with relevant clinical data were included in our meta-analysis. The studies included 2 types of cancers, namely lung and ovarian cancers. TUBA4B expression in these studies was all measured via quantitative real-time polymerase chain reaction.
Our meta-analysis included 3109 cases with OS (23 studies), 1568 cases with DFS (10 studies), and 887 cases with RFS (9 studies). The regions represented in the studies were USA (13), the West (14) , and Asia (6) . Nine types of cancer were included in the meta-analysis, namely lung (n = 8), colon (n = 7), breast (n = 7), ovarian (n = 3), diffuse large B-cell lymphoma (DLBCL, n = 3), chronic lymphocytic leukemia (CLL, n = 1), glioblastoma (GBM, n = 1), meningioma (n = 1), and melanoma (n = 1). The characteristics of these studies are summarized in Tables 2  and 3 . Fig. 2) , and a significant heterogeneity existed between studies (I 2 = 59.1%, P=0.000). No significant publication bias (Begg's test: Pr > |z| = 0.162, Egg's test: P > |t| = 0.080 > 0.05) was noted in the meta-analysis (Fig. 3A) . Results of the analysis using both fixed and random effect models did not differ.
Because of heterogeneity, subgroups were analyzed for data source, region, and sample size. As shown in Fig. 4 , subgroup meta-analysis of data source (GEO database vs. published articles) proved that TUBA4B was significantly associated with the OS of cancer patients in both GEO database (pooled HR = 1.30, 95% CI: 1.13-1.50, P=0.000) and published articles (pooled HR = 1.66, 95% CI: 1.29-2.13, P=0.000). We found a significant association between TUBA4B and the OS of cancer patients in USA (pooled HR = 1.40, 95% CI: 1.11-1.76, P=0.004) and Asian countries (pooled HR = 1.51, 95% CI: 1.25-1.83, P=0.000). However, the association was not significant in Western regions (pooled HR = 1.18, 95% CI: 0.97-1.44, P=0.092; I 2 = 48.3%, P=0.072; Fig. 5 ). Subgroup meta-analysis of the sample size indicated a significant correlation between TUBA4B and the OS of cancer patients in both sample size of >100 (pooled HR = 1.29, 95% CI: Cell and RFS in cancer patients. A. No significant publication bias existed for OS (Begg's test: Pr > |z| = 0.162, Egg's test: P > |t| = 0.080 > 0.05). B. No significant publication bias existed for DFS (Begg's test: Pr > |z| = 0.128, Egg's test: P > |t| = 0.087 > 0.05). C. No significant publication biases existed for RFS (Begg's test: Pr > |z| = 0.404, Egg's test: P > |t| = 0.355 > 0.05).
Fig. 4.
Forest plot of the subgroup meta-analysis of the association between TUBA4B expression and OS in cancer patients based on published articles and the GEO database. To maximize clinical relevance, subgroups were analyzed based on tumor types. We found that TUBA4B was a risk factor for the poor prognosis of lung cancer (pooled HR = 1.24, 95% CI: 1.03-1.49, P=0.021), colon cancer (pooled HR = 1.67, 95% CI: 1.02-2.74, P=0.042), breast cancer (pooled HR = 1.52, 95% CI: 1.10-2.12, P=0.012), and ovarian cancer (pooled HR = 1.67, 95% CI: 1.18-2.36, P=0.004). However, no significant association was noted between TUBA4B and OS for DLBCL, CLL, and neurotumors. These results were strengthened by the low heterogeneity between the studies (Fig. 7) . Subgroup analysis of pooled HR of OS in different types of cancer with decreased TUBA4B expression, 95% CI, heterogeneity, and overall effect are detailed in Table 4 . Since lung cancer had six GEO datasets and one article ( Fig. 7) and had the largest number of patients in the classification of tumor types (Table 4) , , 100μm) . B, D. Representative images and FISH scores analys lncRNA-TUBA4B staining at stages I-IV (scale bar, 100μm); two-tailed Student's *P < 0.05, **P < 0.01 and ***P < 0.001. , 100μm) . B, D. Representative images and FISH scores analysis of lncRNA-TUBA4B staining at stages I-IV (scale bar, 100μm); two-tailed Student's t-test, *P < 0.05, **P < 0.01 and ***P < 0.001. Fig. 8. Fluorescence in situ hybridization (FISH) of lung cancer tissues. A, C , 100μm) . B, D. Representative images and FISH scores analysis of lncRNA-TUBA4B staining at stages I-IV (scale bar, 100μm); two-tailed Student's t-test, *P < 0.05, **P < 0.01 and ***P < 0.001. Fig. 9 . Forest plot of the association between TUBA4B expression and DFS in cancer patients. we evaluated the expression of TUBA4B in lung cancer tissues for experimental verification by FISH assay. It was found that the lncRNA-TUBA4B was significantly lower expression in tumor tissues than normal lung tissues (Fig. 8A, C) . In addition, we found that the expression of lncRNA-TUBA4B was decreased with the progression of lung cancer stage (Fig. 8B, D) . These results indicate that the patients with low TUBA4B expression have a poor prognosis. Fig. 9 ). Neither significant heterogeneity (I 2 = 29.3%, P=0.175) nor significant publication bias (Begg's test: Pr > |z| = 0.128, Egg's test: P > |t| = 0.087 > 0.05) existed across the studies (Fig. 3B) . A subgroup analysis found that TUBA4B was significantly associated with DFS in colon cancer (pooled HR = 1.49, 95% CI: 1.15-1.95; I 2 = 14.8%, P=0.320) and breast cancer (pooled HR = 1.23, 95% CI: 1.01-1.49; I 2 = 0.0%, P=0.398) (Fig. 10 , Table 5 ). 
Meta-analysis of the association between TUBA4B expression and RFS
A total of 9 studies were included in the meta-analysis of TUBA4B expression and RFS. The HR of the association between decreased TUBA4B expression and RFS in these cancer patients was 1.42 (95% CI: 1.26-1.60, P=0.000; Fig. 11 ). There was no significant heterogeneity (I 2 = 0.0%, P=0.1747) and publication bias (Begg's test: Pr > |z| = 0.404, Egg's test: P > |t| = 0.355 > 0.05) across the studies (Fig. 3C) . We used both fixed and random effect models to calculate the effect of TUBA4B on patient survival and found that the results were not markedly different.
Sensitivity analysis
Sensitivity analysis was performed by removing each study alternately from the pooled analysis. This analysis aimed to evaluate the effect of the removed study on the pooled HRs. Removing any included study had no significant impact on the meta-analysis outcomes, suggesting the robustness of the results. The sensitivity analysis revealed that the pooled HR of OS (Fig. 12) , DFS (Fig. 13) , and RFS (Fig. 14) were reliable.
Discussion
This meta-analysis used the online databases PubMed, Embase, and Web of Science and the GEO database to evaluate the association between TUBA4B expression and survival according to clinical indicators. A total of 23 studies comprising 3109 samples of OS were included in this meta-analysis, in which 21 studies were identified via the GEO database, representing 2879 samples. At present, only few clinical studies have focused on TUBA4B because of the small number of patients with such condition. Therefore, a classical meta- analysis may overestimate the effect of TUBA4B in tumors. The establishment of tumor databases, such as GEO and The Cancer Genome Atlas, allows for a more extensive and accurate study of tumor molecular markers [18, 19] . The inclusion of GEO data allows for a more extensive data source and more realistic results. At present, only 2 articles demonstrated that low lncRNA-TUBA4B may be a predictor of poor prognosis in non-small-cell lung cancer and ovarian cancer [12, 13] . However, the sample size of these studies is small. This meta-analysis evaluated the value of TUBA4B as a marker of tumor prognosis. Through systematic analysis, we found that TUBA4B expression was low in many types of tumors. We evaluated the expression of TUBA4B in lung cancer tissue arrays for experimental verification by FISH assay and the results were consistent with the analysis. LncRNA-TUBA4B was lower expression in tumor tissues than normal lung tissues (P<0.001). By combining the HRs from Cox analysis, we found that TUBA4B was an independent risk factor for OS in cancer patients (pooled HR = 1.33, 95% CI: 1.16-1.52, P=0.000). In addition, TUBA4B can be considered an independent prognostic risk factor for DFS (HR = 1.25, 95% CI: 1.06-1.48, P=0.007) and RFS (HR = 1.42, 95% CI: 1.26-1.60, P=0.000) in cancer patients.
To explore the heterogeneity, subgroups were analyzed, and the results revealed that TUBA4B expression can be used as a prognostic factor for OS, DFS, and RFS. We found that TUBA4B significantly affected RFS (HR = 1.42, 95% CI: 1.26-1.60, P=0.000), and the heterogeneity (I 2 = 0.0%, P= 0.1747) was small, thereby strengthening our results. Moreover, both Begg's and Egg's tests identified no significant publication bias about the independent prognostic role of TUBA4B in OS, DFS, and RFS. A sensitivity analysis using both fixed and random effect models showed no significant differences. In summary, our analysis is reliable, and the low expression of TUBA4B is associated with poor prognosis.
In contrast, our meta-analysis has several limitations. First, differences in article quality across studies can cause bias in the meta-analysis. Second, TUBA4B expression in 2 published articles are not directly obtained from the primary studies and were estimated using a software, and this could lead to an error in the HR value and may also increase the original value of heterogeneity. Third, the length of survival and treatment of patients was significantly correlated, and these differences might markedly affect HR and thus result in heterogeneity. In addition, most included papers reported positive results, which may generate publication bias. Therefore, the significance of TUBA4B in predicting the prognosis of cancer patients may be slightly overestimated. Thus, the study results must be confirmed in a larger sample in a polycentric and randomized controlled prospective study.
Conclusion
The low expression of TUBA4B was significantly associated with poor OS, DFS, and RFS in cancer patients. The results of our meta-analysis suggest that TUBA4B can be a novel biomarker for the prognosis of various cancers. Further research is needed to explore the role of TUBA4B in human cancer.
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